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Abstract A prospective study was conducted during a one-
year period between 2006 and 2007 to describe the
epidemiology of Clostridium difficile-associated disease
(CDAD) at University Hospital Basel, Switzerland (UHBS)
and to determine phenotypic and genotypic features of C.
difficile strains isolated at the Microbiology Laboratory
UHBS including strains from regional non-university
hospitals. We prospectively identified 78 CDAD cases at
UHBS with an incidence of 2.65/1,000 hospitalised patients
or 2.3/10,000 patient-days. Sixteen patients (20.5%) were
infected with clindamycin-resistant strains of PCR-ribotype
027 during an outbreak at the geriatric hospital. Among 124
single-patient isolates, 28 (22.6%) were resistant to moxi-
floxacin and 34 (27.4%) were resistant to clindamycin, but
all remained susceptible to metronidazole and vancomycin.
Of 102 toxigenic isolates, 19 (18.7%) had an 18-bp deletion
in the tcdC gene, eight (7.8%) a 39-bp deletion, and one
(1.0%) a 54-bp deletion. Genes for binary toxin were
present in 27 (21.8%). PCR-ribotype 027 was associated
with older age (median age 83.5 vs. 65.5 years, p<0.0001)
and longer duration of hospitalisation before onset of
disease (median 15.5 vs. 9 days, p=0.014) with a trend
towards higher crude mortality, more severe disease, and
previous use of macrolides compared to ribotype non-027.
Overall, severe disease correlated with use of a nasogastric
tube and surprisingly shorter duration of hospitalisation
before onset of disease. Today, laboratory-based and epide-
miological surveillance systems are required to monitor
CDAD cases and emergence of new epidemic strains.
Introduction
Clostridium difficile is one of the most important nosoco-
mial pathogens. It is the most frequent cause of antibiotic-
associated diarrhoea [1, 2]. C. difficile-associated disease
(CDAD) has become an increasing clinical problem in the
hospital setting as well as in the community [3]. The
spectrum of disease is wide—from asymptomatic coloniza-
tion, mild or self-limiting diarrhoea to life-threatening
pseudomembranous colitis [4]. Recently, a new virulent C.
difficile strain characterised as toxinotype III, North
American pulsed-field type 1, restriction-endonuclease
analysis group type BI, and PCR-ribotype 027 has emerged
worldwide causing outbreaks in North America and Europe
[4, 5]. CDAD due to this hypervirulent strain is associated
with increased morbidity and mortality [6–8]. It has been
suggested that increased virulence results from hyperpro-
duction of toxins A and B as a result of deletions in the
putative negative regulator gene (tcdC) leading to truncated
amino acid residues with insufficient function [9]. More
severe disease and a higher case-fatality rate have also been
associated with C. difficile strains producing actin-specific
ADP-ribosyltransferase (binary toxin) [6, 10]. Other toxin-
variant strains such as toxin A-negative/toxin B-positive
and toxin A-positive/toxin B-negative strains are also
associated with disease or outbreaks [11, 12].
In this study, we aimed to determine phenotypic and
genotypic features of C. difficile strains isolated at the
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Microbiology Laboratory of the University Hospital Basel,
Switzerland during a one-year period between 2006 and
2007. Furthermore, we prospectively identified all CDAD
cases including a first cluster of 16 CDAD patients with
clindamycin-resistant C. difficile PCR-ribotype 027 at
University Hospital Basel and the affiliated geriatric hospital
in Basel (UHBS) [13] during the same study period. We
analysed clinical and epidemiological patient data as well as
the corresponding C. difficile isolates in order to compare
strain characteristics with clinical presentation.
Material and methods
Microbiological analyses
All faecal specimens from patients suspected of having
CDAD and submitted to the laboratory for C. difficile testing
between June 2006 and July 2007 were included in the
study. Specimens were sent by UHBS and surrounding
hospitals. Samples were tested for toxin A/B using the
enzyme-linked immunosorbent assay C.DIFF TOX A/B II
(TechLab/Wampole, Blacksburg, VA, USA) according to
manufacturer’s instructions and simultaneously cultured as
previously described [14]. DNA was extracted with LC
MagnaPure systems (Roche Diagnostics, Rotkreuz, Switzer-
land). A single patient isolate was defined as an isolate per
patient including repetitive isolates if at least four weeks
apart. Genes for toxins A/B and binary toxin were detected
by PCR [15]; the tcdC genotype was determined by
sequencing [15, 16]. Ribotyping was performed by the
methods of Stubbs et al. [17]. Antibiotic susceptibility to
metronidazole, moxifloxacin, clindamycin, and vancomycin
was determined by Etest (AB Biodisk, Solna, Sweden) and
interpreted in accordance with the Clinical and Laboratory
Standards Institute [18]. MICs ≥8 mg/l for moxifloxacin and
MICs ≥8 mg/l for clindamycin were regarded as resistant;
MICs ≤8 mg/l for metronidazole and MICs ≤2 mg/l for
vancomycin were deemed susceptible.
Clinical data and definitions
The UHBS is a 680-bed tertiary care centre with 27,000
admissions and 167,000 outpatients per year. In 2001, the
UHBS initiated a surveillance system for C. difficile. Cases
are classified as asymptomatic carrier, mild or severe
CDAD. For the purpose of this study, additional data from
cases were prospectively completed by full-chart review
using a standardized case report form over 12 months. Data
cleaning was performed by manually reviewing the charts
by a board-certified infectious diseases specialist and by
checking for outliers in the analyses. The following date
were collected: demographic data (age, sex), duration of
hospitalisation, hospital ward, symptoms of CDAD (diar-
rhoea defined as more than three episodes per day), fever,
relevant laboratory results (C-reactive protein, white blood
cell count, albumin), antibiotic therapy, comorbidity using
the Charlson index [19], McCabe classification [20], and
Table 1 Phenotypic and genotypic features of 124 Clostridium difficile single-patient strains isolated during a one-year period at the
Microbiology Laboratory, University Hospital Basel
All (n=124) PCR-ribotype 027 (n=18) PCR-ribotype non-027 (n=106)
n (%) n (%) n (%)
Moxifloxacin resistant 28 (22.6) 18 (100) 10 (9.4)
Clindamycin resistant 34 (27.4) 18 (100) 16 (15.1)
Both resistant 21 (16.9) 18 (100) 3 (2.8)
Toxine A/B profile
Tox A –/B – 21 (16.9) 0 21 (19.8)
Tox A +/B– 2 (1.6) 0 2 (1.9)
Tox A +/B + 101 (81.5) 18 (100) 83 (78.3)
Binary toxin + 27 (21.8) 18 (100) 9 (8.5)
tcdC genotype (n) tcdC-sc1 (18) tcdC-A (8), tcdC-UHBS2 (1)
tcdC genotype (n=102)
Wildtype WT-1 7 (6.9) 0 7 (8.3)
Wildtype WT-2 3 (2.9) 0 3 (3.6)
Wildtype WT-3 4 (3.9) 0 4 (4.8)
Wildtype WT-4 60 (58.8) 0 60 (71.4)
tcdC-sc1 (18-bp deletion) 18 (17.7) 18 (100) 0
tcdC-A (39-bp deletion) 8 (7.8) 0 8 (9.5)
tcdC-B (18-bp deletion) 1 (1.0) 0 1 (1.2)
UHBS-2 (54-bp deletion) 1 (1.0) 0 1 (1.2)
tcdC putative negative regulator gene, + presence, – absence
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underlying diseases according to the International Classifi-
cation of Diseases (ICD, 10th edition). They were matched
with the microbiological results obtained from C. difficile
patient isolates during the same study period including
cases with clindamycin-resistant C. difficile PCR-ribotype
027 from a cluster previously reported [13]. CDAD was
defined by the presence of diarrhoea and a positive result
for toxin A/B or a patient suffering from diarrhoea, a
positive C. difficile stool culture, a clinical diagnosis in the
chart, plus a therapy with vancomycin or metronidazole
[21, 22]. A complicated clinical course was defined as
admission to an intensive care unit, need for surgical
intervention, or death. Recurrent CDAD was considered if a
positive toxin or stool culture was detected within three
months after first diagnosis; reinfection was defined when a
new CDAD episode was diagnosed after three months
during the same hospitalisation or during a new hospi-
talisation. A case of CDAD was classified as severe if one
of the following complications occurred: paralytic ileus,
toxic megacolon, severe dehydration, or severe sepsis.
Cases were classified as moderate if at least three or as
mild if less than three of the following symptoms were
present: fever >38.5°C, severe diarrhoea, abdominal pain,
and leukocytosis (>109/l).
Statistical analyses
SPSS statistical software version 14.0 (SPSS Inc., Chicago,
IL, USA) was used for statistical analysis. Odds ratios
(OR) of binary, categorical, or continuous variables were
determined by logistic regression (univariate). Statistical
significance of dichotomous variables was achieved by
using χ2, Fisher’s exact, or nonparametric tests when
appropriate.
Results
Analysis of strains
The phenotypic and genotypic features of 124 single-
patient isolates are given in Table 1. A total of 98 isolates
(79%) were obtained from UHBS and 26 (21%) from
surrounding hospitals. Overall, 103 strains (83.1%) were
toxigenic (101 toxin A and B positive, two toxin A positive
and B negative). PCR-ribotype 027 was detected in 18
isolates. The tcdC gene was not detected in 1/103 (1%)
toxigenic isolates (strain was toxin A positive and B
negative). Most frequent tcdC genotypes were wild-types,
tcdC-sc1, and tcdC-A (Table 1). Genotypes tcdC-WT1 to
WT4 showed no deletions in their sequences and were
therefore considered as wild-type (GeneBank accession no.
EU075382, EU075378, EU075379, and EU075380). tcdC-A
Table 2 Clinical features of 78 patients with Clostridium difficile-
associated disease (CDAD) at the University Hospital Basel,
Switzerland
Characteristic n (%)
Sex
Male 38 (48.7)
Age, years
≤50 16 (20.5)
51–65 14 (18.0)
>65 48 (61.5)
Classification of disease
Mild 49 (62.8)
Moderate 22 (28.2)
Severe 5 (6.4)
Complicated clinical coursea 25 (32.1)
Death (within 30 days) 7 (9.0)
Follow-upb
Recurrence 3 (3.8)
Reinfection 2 (2.6)
Development of diarrhoea
Community-onset (prior or within 2 days) 2 (2.6)
Hospital associated (between 2–14 days) 43 (55.1)
Hospital associated (after 14 days) 32 (42.3)
Underlying disease
Rehabilitation 20 (25.6)
Neoplasm 12 (15.4)
Infectious disease 11 (14.1)
Cardiovascular system disease 6 (7.7)
Respiratory disease 3 (3.8)
Others 26 (33.3)
Duration of hospitalisation before onset of diarrhoea,
days (median [IQR])
11.5 (5–22)
Previous use of antibiotics
Any antibiotic 71 (91.0)
Penicillins+betalactamase inhibitor 42 (53.8)
Cephalosporins 12 (15.4)
Quinolones 18 (23.1)
Macrolides 4 (5.1)
Clindamycin 1 (1.3)
Other 18 (23.1)
Duration of antibiotic therapy, days (median [IQR]) 8 (6–12)
Use of protone pump inhibitors 47 (60.3)
Laboratory parameters at time of diagnosis
White blood cell count, >109/l 41 (52.6)
Albuminaemia, <35 g/l 60 (76.9)
C-reactive protein, >40 mg/l 49 (62.8)
Fever >38.5 °C 24 (30.8)
McCabe score
No fatal disease 54 (69.2)
Fatal disease in the following 5 years 17 (21.8)
Fatal disease in the following 0.5 year 7 (9.0)
Charlson index (mean ± SD) 2.6 (±1.9)
Predisposing factors
Previous surgery (1 month) 26 (33.3)
Cancer 12 (15.4)
Nasogastric tube 12 (15.4)
Chemotherapy 12 (15.4)
Immunosupression 9 (11.5)
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(39-bp deletion), tcdC-B (18-bp deletion), and tcdC-sc1
(18-bp deletion plus single nucleotide deletion at position
117) correspond to genotypes previously described [9, 16]
whereas the sequence of tcdC-UHBS2 with a 54-bp deletion
is newly recognized (GeneBank accession no. EU075381).
All strains with ribotype 027 were moxifloxacin resistant
(MIC >32 mg/l, sensitivity 100%), and the frequency of
resistance to moxifloxacin among non-027 strains was 9.4%
(specificity 90.6%) (Table 1). Among toxigenic strains,
MIC50 and MIC90 for metronidazole and vancomycin were
0.064 mg/l and 0.25 mg/l, 0.5 mg/l and 1.5 mg/l, respec-
tively, and therefore interpreted as susceptible.
Epidemiological data and patient characteristics
Among the microbiologically analysed single-patient iso-
lates during the study period, 78 fulfilled the case definition
of CDAD and complete data from chart review was
available. Among these, ten CDAD cases were toxin-
negative but suffered from diarrhoea, were C. difficile
culture positive, and were treated for CDAD. In eight cases,
the strain was not available for further microbiological
analysis. Overall, incidence was 2.65 per 1,000 hospitalized
patients and 2.3 per 10,000 patient-days. Among all CDAD
cases, 61.5% were older than 65 years, 62.8% had a mild
clinical course, crude mortality was 9%, frequency of
community-onset of CDAD was 2.6%, and recurrence rate
was 3.8% (Table 2). The median duration of hospitalisation
before onset of diarrhoea was 11.5 days; 91% of patients
had documented antibiotic therapy before disease onset and
most common underlying disease/diagnosis was rehabilita-
tion, neoplasm, and infectious disease. Only four (5.1%)
did not receive a specific treatment, but all of them were
toxin-positive.
Table 2 (continued)
Characteristic n (%)
Hospital ward
Internal medicine 33 (42.3)
Surgical department 10 (12.8)
Intensive care unit 7 (9.0)
Geriatric 24 (30.8)
Others 4 (5.1)
IQR interquartile range, SD standard deviation
a Defined as admission to an intensive care unit, surgical intervention,
or death
b At least one or more than one recurrence or reinfection
Table 3 Comparison of Clostridium difficile-associated disease (CDAD) patients infected with PCR-ribotype 027 versus non-027 strains
PCR-ribotype
Variable 027 strains (n=16) Non-027 strains (n=44) OR (95% CI) p
Age, years (median, IQR) 82.5 (78.5–91.5) 65.5 (53.5–77) <0.0001
Moderate to severe CDAD 7 7 (43.8) 15(34.1) 1.4 (0.43–4.52) 0.57
Complicated clinical coursea (n, %) 4 (25.0) 17 (38.6) 0.53 (0.15–1.89) 0.33
Follow-upb 4 (25.0)
Recurrence 1 (6.2) 2 (4.6) 1.41 (0.12–16.67) 0.79
Reinfection (n, %) 1 (6.2) 1 (2.3) 2.86 (0.17–47.62) 0.45
Death (within 30 days) 3 (18.8) 4 (9.1) 2.3 (0.46–11.11) 0.31
Duration of hospitalisation before onset of diarrhoea
(median days, IQR)
15.5 (12.5–50.5) 9 (5–18) 0.014
Duration of antibiotic therapy, days (median, IQR) 9.5 (6.5 - 13) 7.5 (5–13) 0.3
Use of protone pump inhibitors (n, %) 9 (56.3) 27 (61.4) 0.81 (0.25–2.56) 0.72
Previous use of antibiotics (n, %)
Beta-lactam antibiotics 12 (75.0) 31 (70.5) 1.26 (0.34–4.63) 0.73
Quinolones 6 (37.5) 9 (20.5) 2.33 (0.67–8.14) 0.18
Macrolides 3 (18.8) 1 (2.3) 9.92 (0.95–103.70) 0.054
Laboratory parameters at time of diagnosis (n, %)
White blood cell count > 109/l 9 (56.3) 22 (50.0) 1.28 (0.41–4.0) 0.67
Albuminaemia < 35 g/l 10 (62.5) 34 (77.3) 0.49 (0.14–1.69) 0.26
C-reactive protein > 40 mg/l 8 8 (50.0) 28 (63.6) 0.57 (0.18–1.82) 0.34
Toxin A/B positive directly from stool c (n, %) 9 (56.3) 23 (52.3) 1.18 (0.37–3.70) 0.79
95% CI 95% confidence interval, IQR interquartile range
a Defined as admission to an intensive care unit, surgical intervention, or death
b At least one or more than one recurrence or reinfection
c All cases were toxin-positive either directly from stool or by toxigenic culture
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Clinical and laboratory features in patients infected
with C. difficile PCR-ribotype 027 and non-027
Comparing 60 patients for whomPCR-ribotyping results were
available, we found that patients infected with C. difficile
ribotype 027 (16 patients, or 20.5% of total CDAD cases)
were significantly older than non-027 patients (median age
82.5 vs. 65.5 years, p<0.0001, Table 3) and were hos-
pitalised longer before onset of diarrhoea (median 15.5 vs.
9 days, p=0.014). Although statistically not significant, there
was a trend towards more cases of moderate to severe
CDAD in the 027 group (43.8% vs. 34.1%, p=0.57), higher
crude mortality (18.8% vs. 9.1%, p=0.31), longer duration
of antibiotic therapy before CDAD (median 15.5 vs. 9.0 days,
p=0.31), as well as previous use of quinolones (37.5% vs.
25.7%, p=0.18) and macrolides (18.8% versus 2.3%, p=
0.054). Recurrence and reinfection rate was generally low
(2.3–6.2%). Toxin A/B was detected in only half of the
patients directly in stool specimens and would have been
missed if toxin assay was performed alone (Table 3), but
repeated toxin testing from C. difficile cultures from
specimens that were toxin-negative directly from stool
considerably increased sensitivity. In the non-027 group,
seven patients underwent chemotherapy compared to zero
patients in the 027 group.
Disease severity according to strain and patient
characteristics
Disease severity of CDAD according to strain and patients’
characteristics is summarized in Table 4. For two patients,
the severity of disease was not assessable. The univariate
analysis showed that moderate to severe CDAD is
statistically significant associated with use of a nasogastric
tube and with a shorter hospital stay before onset of
diarrhoea (Table 4). Toxin A/B positivity directly detected
from stool (instead of positive only from culture isolate
testing) was significantly associated with moderate to
severe disease ( p=0.048). We did not observe an associ-
ation between severity of disease and PCR-ribotype 027,
tcdC genotype, as well as presence of binary toxin A/B.
There was a trend towards more frequent recurrences and
reinfection in the more severe disease group; however, the
sample size was too small to infer an association.
Table 4 Disease severity of Clostridium difficile-associated disease (CDAD) cases according to strain and patients’ characteristics
Variable No. of patients with
available information
Disease severity of CDAD OR (95% CI) p
Moderate to severe Mild
Age, years (median, IQR) 76 70 (55–83) 73 (53–85) 0.88
Gender (n, %) 76
Male 14 (51.9) 23 (46.9) 1.22 (0.48–3.13) 0.68
Follow-upa
Recurrence (n, %) 76 2 (7.4) 1 (2.0) 3.85 (0.33–50.0) 0.25
Reinfection (n, %) 76 1 (3.7) 1 (2.0) 1.85 (0.11–33.33) 0.665
Death (within 30 days) (n, %) 4 (14.8) 3 (6.1) 2.63 (0.55–12.5) 0.22
Predisposing factors (n, %)
Previous surgery (within 3 months) 76 3 (11.1) 5 (10.2) 1.09 (0.24–5.0) 0.9
Cancer 76 3 (11.1) 9 (18.4) 0.56 (0.14–2.27) 0.4
Nasogastric tube 76 7 (25.9) 4 (8.2) 4 (1.03–14.29) 0.03
Chemotherapy 76 1 (3.7) 11 (22.4) 0.13 (0.02–1.09) 0.06
Laboratory parameters at time of diagnosis (n, %)
Albuminaemia <35 g/l 67 23 (95.8) 35 (81.4) 5.26 (0.62–50.0) 0.09
C-reactive protein >40 mg/l 73 20 (74.0) 27 (58.7) 2.01 (0.71–5.69) 0.19
Duration of hospitalisation before onset of
diarrhoea, days (median, IQR)
76 8 (4–13) 15 (8–26) 0.002
Duration of antibiotic therapy, days (median, IQR) 6 (3–11) 9 (7–12) 0.08
PCR-ribotype 027 (n, %) 58 7 (31.8) 9 (25.0) 1.4 (0.43–4.52) 0.57
Binary toxin positive (n, %) 68 8 (36.4) 14 (30.4) 1.31 (0.45–3.82) 0.63
Toxin A/B positive directly from stool (n, %) 60 17 (70.8) 16 (44.4) 3.13 (1.02–9.09) 0.048
tcdC genotype (n, %) 58
tcdC-A (39-bp deletion) 1 (4.5) 4 (11.1) 0.43 (0.05–4.0) 0.45
tcdC wildtype (no deletion) 14 (63.6) 22 (61.1) 1.32 (0.52–3.45) 0.56
95% CI 95% confidence interval, IQR interquartile range
a At least one or more than one recurrence or reinfection
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Discussion
Overall, the incidence of 2.65 CDAD/1,000 hospitalized
patients or 2.3/10,000 patient-days was comparable to a study
out of the Netherlands in 2005 (0.1–4.6, median 1.6/1,000
patient admissions) [23] and from a recent European survey
(0.13–7.1/10,000 patient-days) [6]. The incidence of CDAD
remained stable at the University Hospital, but increased
during an outbreak with C. difficile PCR-ribotype 027 in
January 2007 at the affiliated geriatric hospital [13]. The
slightly higher incidence compared to the Netherlands may
be partly explained by the definitions used. The new
guidelines such as those issued by the European Centre for
Disease Prevention and Control (ECDC) define CDAD more
stringently [4, 24] than what was used in our study. These
new guidelines require the detection of toxin that was
negative in ten (13%) of our cases, but fulfilled the Centers
for Disease Control and Prevention (CDC) surveillance
definition [22].
CDAD cases were similar to those of other European
countries regarding age, sex, and severity of disease [10,
23]. In contrast to these studies, community-onset CDAD
was rare (only 2.6%) in this study and the recurrence rate
was lower.
Among all C. difficile strains isolated at the Microbiology
Laboratory during the study period, rates of resistance to
moxifloxacin and clindamycin were overall rather low, but in
the range of a recent European survey [6]. Moxifloxacin
resistance was highly associated with the presence of PCR-
ribotype 027; however, these strains were isolated from an
outbreak, potentially biasing the strength of this association.
Comparing CDAD due to PCR-ribotype 027 with non
027, ribotype 027 was significantly associated with older
age and longer duration of hospital stay before onset of
disease. Although a trend was seen towards higher crude
mortality, a more severe clinical course, previous use of
macrolides, and a longer duration of antibiotic therapy in
the 027 patient group, these findings did not reach a
statistically significant level, possibly due to small sample
size. However, results from previous reports support the
observed trends [6, 7]. In contrast to the latter studies, our
027 strains were all clindamycin-resistant. It is noteworthy
that previous use of macrolides was more strongly
associated with PCR-ribotype 027 than use of quinolones,
but both were statistically not significant.
Severe to moderate disease correlated with use of a
nasogastric tube and shorter duration of hospitalisation
before onset of diarrhoea. Strikingly, the clinical course of
CDAD in patients under chemotherapy was mild; these
patients were predominantly cared for in a special haema-
tological unit where immediate treatment with metronida-
zole after onset of any kind of diarrhoea is standard of care.
Disease severity was not linked to the presence of tcdC
deletions or binary toxin in contrast to previous findings [6,
10]. However, the percentage of binary-toxin positive
strains among CDAD cases was quite high (37%) compared
to the average among all strains isolated at the laboratory
(22%) from patients with and without clinical symptoms.
Patients with toxin-positive stool specimens experienced a
more severe disease (compared to patients with toxin-
negative faeces but with a toxigenic culture result), possibly
due to higher stool toxin levels. The disease is mediated by
toxins A and B, but toxin levels and bacterial counts in stool
are probably affected by many factors and there seems to be
no correlation between severity of disease and faecal toxin
level [4, 25]. Surprisingly, two strains were toxin A positive
but toxin B negative by the PCR method we used. They
were isolated from two patients without CDAD diagnosis.
This is a rare observation that requires confirmation [11].
A limitation of our study is the relatively small number of
total CDAD cases and the small subgroup of patients
infected with ribotype 027 during the 12-month period.
However, all consecutive cases were included, clinical data
were complete and comprehensive, and isolates were
genotypically and phenotypically well characterised. The
follow-up period varied but was at least one month, and we
cannot rule out that recurrences were treated in the outpatient
setting. But seriously ill patients requiring hospitalization are
unlikely to go elsewhere since the University Hospital is the
only tertiary care hospital in the region.
Based on our study, we propose the introduction of
laboratory-based and epidemiological surveillance systems,
at least periodically and in populations at high risk. Suscep-
tibility testing of culture isolates for moxifloxacin may serve
as a basic screening marker for the epidemic ribotype 027
strains. Incidence and clinical presentation of CDAD cases
must be monitored combined with molecular characterisation
of strains to detect emergence of new epidemic strains.
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